Observed Signal · Sep 2, 2026 · Funding · Source: EU-Startups (European Venture) · Impact: 1/5 · Sentiment: Neutral
UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform
London-based Pharosyn, an AI-powered competitive intelligence platform for biopharma, has raised €2.5 million in a funding round led by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance. The company plans to expand its platform and support wider adoption across pharmaceutical commercial and portfolio strategy teams. Founded in 2025 by Stephen Cowley and Joshua Hampson, Pharosyn monitors clinical, regulatory, and commercial data sources to produce strategic reports tailored to an organisation's pipeline. The funding is part of a broader trend of AI investment in pharma, with EU-Startups reporting approximately €75.3 million across seven comparable rounds this year.
Minor funding round for a pharma AI startup; limited direct impact on AdTech.
Track Real-Time Funding Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Pharosyn raised €2.5 million in a funding round.
- The round was led by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance.
- Pharosyn is an AI-powered competitive intelligence platform for biopharma.
- The company was founded in 2025 by Stephen Cowley and Joshua Hampson.
- Senior directors at top-10 pharmaceutical companies reportedly use Pharosyn.
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Proximal Ventures Raises $27.5M for AI Drug Development Fund
Proximal Ventures, founded by former SignalFire investor Sahir Raoof, has raised $27.5 million for its debut venture capital fund. The fund will invest in pre-seed and seed-stage startups applying AI to drug development tools, infrastructure, and services. Proximal has already backed seven startups, including ChronicleBio, which uses AI to analyze biological and medical data for chronic disease research. The fund's backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Dimension Capital co-founders. Raoof, who previously worked at Flatiron Health and Iterative Health, aims to capture pharmaceutical spending by offering AI-driven services that are faster and cheaper than traditional outsourcing. The fund will write checks between $500,000 and $1.5 million.
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
Receive all future signals for Funding in your executive briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.
